Who owns MoonLake Immunotherapeutics?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of MLTX from SEC Form 13F filings across 169 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 169 institutions disclosed 72.7M shares of MoonLake Immunotherapeutics worth $850.1M — about 85.1% of shares outstanding; the largest disclosed holder is BVF INC/IL. Source: SEC Form 13F filings, parsed by EvidInvest.
169
13F holders
$850.1M
value, 2026 filers
85.1%
of shares outstanding (72.7M sh)
34
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of MLTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | 16.0M | $187.2M | 6.2% | 18.7% | 0.0% |
| 2 | Deep Track Capital, LP | 8.1M | $94.8M | 1.5% | 9.5% | +15.8% |
| 3 | T. Rowe Price Investment Management, Inc. | 5.2M | $61.1M | 0.0% | 6.1% | +21.9% |
| 4 | D. E. Shaw & Co., Inc. | 3.5M | $40.8M | 0.0% | 4.1% | +3.6% |
| 5 | Cormorant Asset Management, LP | 2.9M | $33.4M | 2.2% | 3.3% | -10.9% |
| 6 | Weiss Asset Management LP | 2.3M | $27.4M | 0.3% | 2.7% | -9.3% |
| 7 | TWO SIGMA INVESTMENTS, LP | 2.0M | $23.1M | 0.0% | 2.3% | +15.2% |
| 8 | JPMORGAN CHASE & CO | 1.9M | $21.7M | 0.0% | 2.2% | +36.4% |
| 9 | Qube Research & Technologies Ltd | 1.8M | $21.0M | 0.0% | 2.1% | +262.0% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1.7M | $20.1M | 0.0% | 2% | +167.0% |
| 11 | CITADEL ADVISORS LLC | 1.7M | $20.0M | 0.0% | 2% | -13.5% |
| 12 | Trails Edge Capital Partners, LP | 1.7M | $19.7M | 2.8% | 2% | +124.0% |
| 13 | MILLENNIUM MANAGEMENT LLC | 1.5M | $18.0M | 0.0% | 1.8% | +141.2% |
| 14 | Logos Global Management LP | 1.5M | $17.6M | 0.9% | 1.8% | -43.9% |
| 15 | Vivo Capital, LLC | 1.4M | $16.4M | 1.8% | 1.6% | 0.0% |
| 16 | BlackRock, Inc. | 1.4M | $16.1M | 0.0% | 1.6% | +26.0% |
| 17 | MORGAN STANLEY | 1.0M | $11.9M | 0.0% | 1.2% | +80.7% |
| 18 | GREAT POINT PARTNERS LLC | 855,813 | $10.0M | 2.4% | 1% | 0.0% |
| 19 | RICE HALL JAMES & ASSOCIATES, LLC | 839,945 | $9.8M | 0.5% | 1% | +357.0% |
| 20 | ALGERT GLOBAL LLC | 762,031 | $8.9M | 0.1% | 0.9% | +96.9% |
| 21 | HRT FINANCIAL LP | 760,962 | $8.9M | 0.0% | 0.9% | +12.0% |
| 22 | GOLDMAN SACHS GROUP INC | 708,942 | $8.3M | 0.0% | 0.8% | +447.7% |
| 23 | BANK OF AMERICA CORP /DE/ | 707,846 | $8.3M | 0.0% | 0.8% | -5.9% |
| 24 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 703,390 | $8.2M | 0.0% | 0.8% | -6.3% |
| 25 | Trexquant Investment LP | 637,362 | $7.5M | 0.0% | 0.7% | +68.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.